Soligenix announces synthetic hypericin manufactured at Sterling Pharma

Soligenix (SNGX) has completed the transfer of the manufacturing process for its synthetic hypericin active ingredient under its partnership agreement with Sterling Pharma Solutions. The transfer from Europe to the U.S. included the optimization and implementation of a commercially viable, scalable production process for this important active ingredient, which is used in the topical drug product formulations HyBryte and SGX302 being developed for the treatment of cutaneous T-cell lymphoma and psoriasis, respectively. Synthetic hypericin is a potent photosensitizer that is topically applied to skin lesions. Soligenix and Sterling have enabled cGMP manufacturing for clinical trials with the intent of establishing a long-term commercial manufacturing collaboration.